Brexpiprazole: Phase III started

Lundbeck disclosed in its 2013 earnings that in December it and Otsuka began a double-blind, placebo-controlled, U.S. Phase III trial to evaluate doses of up to 3 mg oral brexpiprazole once daily as a...